The stream · Daily digest
The stream: Sunday, November 1, 2026
1 brief, grouped by desk. Each is two sentences from one primary source, linked to it.
Machine-summarized from primary sources; not independently reported. How we use automation
Clinical trials · 1
-
Abbott reports strong 30-day outcomes in TECTONIC IVL study
The TECTONIC CAD IVL IDE Study enrolled 335 patients and met its primary safety endpoint with a 30-day target lesion failure rate of 0.3%. The study also achieved a primary effectiveness endpoint with procedural success in 97% of patients.
Source: Company press release (PR Newswire), November 1, 2026